Fig. 2: PFS for each cohort and PFS stratified by PD-L1 CPS status. | Nature Communications

Fig. 2: PFS for each cohort and PFS stratified by PD-L1 CPS status.

From: Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

Fig. 2

PFS for each cohort (A) and PFS stratified by PD-L1 CPS status for each cohort (B–E). Shadowed areas represent the confidence intervals for PFS. Statistical comparison by log-rang. NENs neuroendocrine neoplasms, PFS progression-free survival. Source data are provided as a Source Data file.

Back to article page